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Abstract
The Skp2 locus encodes two proteins, Skp2 and Skp2B. The role of Skp2 in the ubiquitin-dependent degradation of
key regulators of the retinoblastoma protein pathway has been well established. More recent work from the
McCormick’s group suggested that Skp2 has an ubiquitin-independent function in the regulation of the p53
pathway. Adding to this observation, we reported that Skp2B also regulates the activity of p53 by degrading a
distinct substrate, prohibitin. Since prohibitin has been implicated in the regulation of the Rb pathway, collectively,
these observations suggest that Skp2 and Skp2B team up against p53 and Rb.
Introduction
The retinoblastoma (Rb) and the p53 pathways are two
major mechanisms of tumor suppression. Disruption of
these pathways is observed in most cancers. This review
focuses on the description of two mechanisms by which
both Rb and p53 pathways are disrupted simultaneously.
First, the loss of the well known p16INK4a/p19ARF
locus and second, the less well known amplification of
the Skp2/Skp2B locus.
The p16INK4a/p19ARF locus regulates the Rb and
p53 pathways
The remarkable genetic organization of some loci sug-
gests that evolution has selected mechanisms to maxi-
mize their biological impact. One example of such
clever organization is the p16
Ink4a/p19
Arf locus. By using
two distinct promoters, this locus allows the expression
of two different proteins using overlapping genetic
material (reviewed in [1]; the p16 protein, a cyclin-
dependent kinase (cdk) inhibitor and ARF, an indirect
regulator of the tumor suppressor gene p53.
The cyclin dependent kinases (cdk) are a family of
protein serine/threonine kinases, which control cell
cycle progression through association with their regula-
tory subunits, known as cyclins. Cyclins are classified
into a large number of subtypes including the D, E,
A and B-type cyclins. Humans encode three D-type
cyclins, cyclin D1, cyclin D2 and cyclin D3. D-type
cyclins associate with cdk4 and 6 to promote the
phosphorylation of the Retinoblastoma (Rb) protein (for
review, [2]). Rb forms a complex with the E2F family of
transcription factors and this represses their activity.
Hyperphosphorylation of Rb results in the release of
E2F, which then activates transcription of genes required
for DNA replication and entry into S phase [3]. One of
the early targets of E2F mediated transcription is cyclin
E that, together with cdk2, acts to maintain Rb
phosphorylation.
Cyclin-cdk complexes are themselves regulated by two
families of cdk inhibitors including p27 of the p21
family, which inhibits cyclin E-cdk2 complexes [4], and
p16 of the INK4 family, which inhibits cyclin D-cdk4/6
complexes [5]. Functional disruption of the tumour sup-
pressors p16
INK4a or Rb or overexpression of cyclin D1
and CDK4 is frequently observed in many cancer types
suggesting that disrupting the ‘Rb pathway’ is an essen-
tial part in oncogenesis [6].
The disruption of the p53 tumor suppressor is also an
essential part of oncogenesis and p53 mutation is one of
the most frequent genetic aberration observed in cancer.
However, in addition to mutations, other mechanisms
have evolved to disrupt this pathway. For example, dis-
ruption of ARF, allows for the accumulation of the ubi-
quitin ligase mdm2, which results in the degradation
and inactivation of p53. Therefore, the loss of the
p16INK4a/p19ARF locus allows for the simultaneous
disruption of both the Rb and p53 pathways.
Overexpression of Skp2 regulates the Rb and
p53 pathways
More recently the overexpression of the F-box protein
Skp2 was found to mediate an alternative mechanism
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F-box proteins act as the substrate recognition subunits
of specific ubiquitin ligase complexes. Linkage of ubiqui-
tin to a protein is a highly organized process involving
the sequential action of an ubiquitin-activating enzyme
(E1), an ubiquitin-conjugating enzyme (E2) and an ubi-
quitin-ligase (E3). When this enzymatic cascade results
in the attachment of a lysine 48 polyubiquitin chain
onto a substrate, it serves as a signal for degradation by
the 26S proteasome. Most of the regulation of the ubi-
quitination pathway occurs at the level of the ubiquitin
ligase. Of particular interest to this review is the ubiqui-
tin ligase complex termed the SCF complex [7-10] that
is composed of Skp1, a cullin, an F-box protein and the
ring finger protein Roc-1[11-13]. F-box proteins act as
adaptors by associating with substrate proteins, bringing
them to the core of the SCF by binding to Skp1 [14].
The SCF
Skp2 complex refers to the SCF in which Skp2 is
the F-box protein. The overexpression of Skp2 has been
linked to the progression of several tumors due to its
involvement in the degradation of a key regulator of the
cell cycle.
Skp2 is involved in the ubiquitin-dependent degrada-
tion of the Cyclin-dependent kinase (Cdk) inhibitor p27
[15,16]. p27 binds to, and inhibits Cyclin E-Cdk2 com-
plexes, and as a result, prevents progression through the
cell cycle. Upon phosphorylation of threonine-187, p27
binds to Cks1 and Skp2 [17], it becomes ubiquitinated
and subsequently degraded. Consequently, the degrada-
tion of p27 leads to the activation of Cyclin E-Cdk2
complexes and hence entry into the S-phase of the cell
cycle. Loss of p27 is a frequent event in several cancer
types and is associated with poor prognosis [18-20].
However, the lack of p27 expression is not due to the
loss of the p27 gene, but rather due to the overexpres-
sion of Skp2 [19].
Skp2 was more recently shown to attenuate the p53
pathway [21] and this function appears to be indepen-
dent of SCF-mediated proteolysis. This was revealed
when an F box-deleted version of Skp2, which cannot
bind to the SCF, was found to be equally potent as an
attenuator of p53. Kitagawa et al, described that Skp2
binds the transcriptional co-activator p300, therefore
blocking the interaction between p300 and p53. As acet-
ylation of p53 by p300 is essential for its activation [22]
Skp2 inhibits the transactivation function of p53.
Therefore, as observed with the loss of the p16Ink4a/
p19Arf locus, overexpression of Skp2 leads to the dis-
ruption of both the Rb and p53 pathways.
Skp2 is not alone, the contribution of Skp2B to the
deregulation of Rb and p53 pathways
Our study of Skp2B recently contributed a new twist to
this story. Like other F-box proteins such as b-TRCP,
Skp2 has been reported to have three alternative splice
forms, Skp2 or Skp2A, Skp2B and Skp2-gamma,
although Skp2-gamma remains uncharacterized.
Skp2 has three important domains: an N-terminal
F-box motif, required for binding to Skp1, followed by
10 consecutive leucine rich repeats (LRR), located near
the C-terminus and required for binding to substrates
(Figure 1). The third important domain is the
C-terminus, as it folds back near the F-box and stabilizes
the interaction with Skp1 (Figure 1).
We identified Skp2B in 2001, and called it originally
Skp2-CTV (C-Terminal Variant) as it is characterized
by the presence of a unique C-terminal domain (Figure
1) [23]. We previously reported that Skp2A and Skp2B
are both overexpressed in breast cancers [24]. We
found that Skp2B differs from Skp2 in several respects,
notably that Skp2B is cytoplasmic while Skp2 is nuclear,
and that, unlike Skp2, Skp2B does not regulate p27
levels [24].
Interestingly, since the isolation of Skp2B, a number of
studies using antibodies that recognize both Skp2 and
Skp2B have described the presence of strong cytoplas-
mic staining in various cancer types, including breast
cancer [18], although the percentage of cytoplasmic
versus nuclear staining was not reported in this breast
cancer study. In prostate cancer within the African-
American population, however, cytoplasmic staining was
found to be predominant. Moreover, the lack of correla-
tion between Skp2 and p27 levels in a large number of
these cases led the authors to conclude that Skp2
expression in prostate cancer pathogenesis might not be
exclusively related to p27 degradation [25]. One obvious
explanation is that the cytoplasmic form is Skp2B, for
which p27 is not a substrate. In support of this conclu-
sion, two additional studies, one in Kaposi’ss a r c o m a ,
and another in cervical cancer, found no correlation
between Skp2 expression and loss of p27. Further, both
of these studies reported a significant percentage of
cytoplasmic staining, which also suggests that Skp2B
overexpression in these tumors may explain their obser-
vations [26,27].
In order to determine the role of Skp2B in breast can-
cer, we established transgenic mice expressing Skp2B
under the mammary-tumor virus (MMTV) promoter.
These mice displayed an accelerated invasion of the
mammary fat pad by the mammary tree during puberty,
an accelerated lobulo-alveolar development, which is
normally restricted to pregnancy, and gross cyst forma-
tion. In addition, they also developed mammary tumors
of varying histology, including high-grade adenocarcino-
mas with undifferentiated pattern [28]. The formation of
tumors was greatly accelerated by pregnancy suggesting
a synergy between the pathways activated by Skp2B
overexpression and those activated during pregnancy.
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formed a 2-hybrid screen using the C-terminal domain
that is unique to Skp2B as the bait and identified two
proteins containing an SPFH domain (Stomatin/Prohibi-
tin/Flotillin/HflK/C). SPFH proteins have been impli-
cated in a variety of functions including as chaperones,
and in senescence and proliferation. The two SPFH pro-
teins isolated as Skp2B associated proteins are the
repressor of the estrogen receptor activity (REA), also
known as prohibitin-related and prohibitin.
Among the co-repressors, the repressor of estrogen
receptor activity (REA) has profound effect on the devel-
opment of the mammary gland [29,30]. REA heterozygote
mice display accelerated invasion of the fat pad and devel-
opment of the mammary gland during pregnancy, which
is associated with an increase in the ER activity [30].
We reported that Skp2B co-immuoprecipitates with
REA and that Skp2B overexpression results in a decrease
in REA levels and an elevation in the activity of the estro-
gen receptor [28]. Our data suggest that since MMTV-
Skp2B transgenic mice display a phenotype closely
related to that observed in REA heterozygote mice [30],
Skp2B represents a novel regulator of the ER and, that
Skp2B overexpression in primary breast cancer, plays a
significant role in breast cancer. However, since REA het-
erozygote mice do not develop mammary tumors while
MMTV-Skp2B mice do, this observation suggested that
Skp2B must have additional substrates.
We later reported that the over-expression of Skp2B
promotes the ubiquitination and subsequent degradation
of prohibitin [31]. Since Prohibitin binds and stimulates
the transcriptional activity of p53 [32], we reasoned that
lost of prohibitin, as a result of Skp2B overexpression,
may disrupt p53 activity and contribute to the formation
of mammary tumor in the MMTV-Skp2B transgenic
mice [31]. In support of this hypothesis we reported
that the activity of p53 is attenuated by the overexpres-
sion of Skp2B both in vitro and in vivo [31].
O fr e l e v a n c et ot h i sr e v i e wi st h ea d d i t i o n a lf i n d i n g
that prohibitin represses the transcriptional activity of
E2F [33-37]. Mechanistically, prohibitin binds to Rb,
Brg-1 and Brm, which are recruited to E2F responsive
promoters by prohibitin to repress E2F-mediated tran-
scription. While the recruitment of Brg-1 and Brm by
prohibitin is independent ofR b ,t h ep r o h i b i t i n - B r g - 1 -
Brm repression of E2F required Rb, suggesting that pro-
hibitin acts to enhance the repressive effect of Rb.
However, it is important to note that a wide number
of distinct functions have been attributed to prohibitin
and a fundamental divergence of opinion regarding the
role of prohibitin in cancer exists. On one hand, strong
evidence suggests that prohibitin function is essential to
maintain mitochondrial function and cellular prolifera-
tion [38-42] and that prohibitin is overexpressed in can-
cer [39]. On the other hand, a large number of studies
indicate that prohibitin acts as a tumor suppressor and
prevents cellular proliferation [32,34,36,37,43-45]. While
this discrepancy appears difficult to reconcile, one key
distinction between these studies is that prohibitin is
reported to be present in multiple cellular locations.
In the mitochondria, prohibitin is found to be required
for proliferation, while prohibitin in the nucleus appears
to inhibit a number of transcription factors such as the
estrogen receptor and the androgen receptor, or to sti-
mulate the growth inhibitory transcription factor p53.
Therefore, if correct, these observations would suggest
that in cancer, maintenance of prohibitin in the mito-
chondria and loss of its nuclear function are both
required for growth.
We therefore propose that the differential regulation
of nuclear and mitochondrial fraction of the prohibitins
by the proteasome may offer a potential mechanism to
reconcile the apparent discrepancies concerning the role
of prohibitins in cancer.
Skp2 and Skp2B: partners in crime
Since Skp2 and Skp2B overexpression in primary breast
cancers is not mutually exclusive [24], we propose a
model for the combined effect of Skp2 and Skp2B
(Figure 2). In this model by degrading their respective
substrates Skp2 and Skp2B affect simultaneously the Rb
and the p53 pathways and therefore the amplification of
the Skp2/Skp2B loci represents a powerful mechanism
of oncogenesis. These observations raise the possibility
that even in the absence of p53 mutations or mdm2
amplification, the activity of p53 may be attenuated due
to the amplification of the Skp2 locus. Further, since
Figure 1 Structure of Skp2 as determined by Schuman et al,
2000. The C-terminal domain is encoded by a different exon in
Skp2B.
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the anti-estrogen drug tamoxifen [18,46] and estrogen
stimulates Skp2 expression [46], while we found that
Skp2B promotes the activity of the estrogen receptor
[28], the combined effect of both Skp2 and Skp2B is
predicted to also activate this pathway. These combined
actions may underline the worst prognosis associated
with Skp2/2B over-expression [21]. Therefore, as for the
lost of the p16INK4a/p19ARF locus, amplification of the
Skp2/Skp2B locus represents an alternative mechanism
of disruption of the Rb and p53 pathways. Since Skp2
and Skp2B differ only at the C-terminal domain but are
otherwise identical, molecules able to inhibit both iso-
forms are predicted to be the most promising.
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